Associated Papers
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer.
Sposito M et al.
Scientific Reports, 2025
Inflammatory Giant Cell Carcinoma of the Lung: Clinicopathologic, Immunohistochemical, and Next-generation Sequencing Study of 14 Cases.
Suster DI et al.
The American Journal of Surgical Pathology, 2024
Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancer.
Huang Y et al.
Chinese Clinical Oncology, 2024
Digenic CHD7 and SMCHD1 inheritance Unveils phenotypic variability in a family mainly presenting with hypogonadotropic hypogonadism.
Wang T et al.
Heliyon, 2024
Concordance of Targeted Sequencing from Circulating Tumor DNA and Paired Tumor Tissue for Early Breast Cancer.
Huang CC et al.
Cancers, 2023
FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response.
Bogatyrova O et al.
European Journal of Cancer (oxford, England : 1990), 2021
Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma.
Liu X et al.
Oncogene, 2021
Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico.
Zheng R et al.
Cancers, 2020
Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling.
Weber S et al.
Cancers, 2020
Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.
Shaib WL et al.
The Oncologist, 2020
High frequency of CHD7 mutations in congenital hypogonadotropic hypogonadism.
Gonçalves CI et al.
Scientific Reports, 2019
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.
Testa U et al.
Cancers, 2018
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
Windon AL et al.
Journal of Gastrointestinal Oncology, 2018
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.
Kato S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
Guffanti F et al.
Neoplasia (new York, N.y.), 2017
Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
Tanizaki J et al.
Lung Cancer (amsterdam, Netherlands), 2016
Novel FGFR1 mutations in Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism: evidence for the involvement of an alternatively spliced isoform.
Gonçalves C et al.
Fertility and Sterility, 2015
Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
Wen YS et al.
Medicine, 2014
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
Morris EJ et al.
Cancer Discovery, 2013
Keratinocytic epidermal nevi are associated with mosaic RAS mutations.
Hafner C et al.
Journal of Medical Genetics, 2012
KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
Tie J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011